| ¿µ¹® | hepatitis | ÇÑ±Û | °£¿° |
|---|---|---|---|
| ¼³¸í | °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁÖµÈ ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°ÀÌ¸ç ±× ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀÎ °Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù ÀÌ»ó °£¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇÏ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª ȯÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î ȯÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, ȯÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁÖ·Î °¡À»¿¡¼ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í û¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼´Â Ȳ´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà ¶§µµ ÀÖ¾î óÀ½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼¼È÷ ¹ßº´ÇÏ´Â °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í Ȳ´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ Ȳ´ÞÀÌ ³ªÅ¸³´Ù. Ȳ´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇÏ´Â Àü°Ý¼º°£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú Áß È²´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í ÇÏ´Â °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇÏ´Â °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈÇϱ⠽±´Ù. |
||
| ¿µ¹® | acute hepatitis | ÇÑ±Û | ±Þ¼º°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, ÀÌ´Â ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇÏ´Â ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°ÀÌ¸ç ³ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇÏ´Â À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀÌ Ã£¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³´Ù. µÚÀ̾î Ȳ´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª Ȳ´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â Ȳ´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» ÇØµµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀÌ Æ¯Â¡ÀÌ¸ç ±Þ¼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º¿î °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀÎ °ÍÀÌ º¸ÅëÀÌ´Ù. |
||
| ¿µ¹® | chronic active hepatitis | ÇÑ±Û | ¸¸¼ºÈ°µ¿°£¿° |
|---|---|---|---|
| ¼³¸í | BÇü °£¿°À̳ª ºñAÇü£ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Ư¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀÇ Ä§À±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ Ȳ´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈÁõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù. |
||
| ¿µ¹® | fulminant hepatitis | ÇÑ±Û | Àü°Ý°£¿° |
|---|---|---|---|
| ¼³¸í | ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º Ȳ»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç ȯÀÚ´Â º¸Åë »ç¸ÁÇÑ´Ù. Ȳ´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ ÀÌ¹Ì Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© Ȳ´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇÏ´Â ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇÏ°Ô µÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇÏ´Â °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, ƯÈ÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù. |
||
| AH | abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro... |
|---|---|
| eIPV | enhanced inactivated polio vaccine |
| HIFBS | heat-inactivated fetal bovine serum |
| HIFCS | heat-inactivated fetal calf serum |
| IFCS | inactivated fetal calf serum |
| IPV | Inactivated Polio-Vaccine |
|---|---|
| IPV | Inactivated poliovirus vaccine |
| AIH | 1)autoimmune hepatitis |
| AAH | Acute alcoholic hepatitis |
| AH | Acute hepatitis |
| vaccines, inactivated | Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins. (12 Dec 1998) |
|---|---|
| inactivated polio vaccine | <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years. (27 Sep 1997) |
| inactivated poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| inactivated serum | <immunology> Serum that has been heated 50°C for 30 minutes to destroy the lytic activity of complement. (05 Mar 2000) |
| acute parenchymatous hepatitis | A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice. Synonym: acute parenchymatous hepatitis, Rokitansky's disease. (05 Mar 2000) |
| anicteric hepatitis | Hepatitis without jaundice. (05 Mar 2000) |
| anicteric virus hepatitis | A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis. (05 Mar 2000) |
| autoimmune hepatitis | <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver. Symptoms are those of chronic active hepatitis. (27 Sep 1997) |
| vaccination, hepatitis a | When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. (12 Dec 1998) |
| vaccination, hepatitis b | Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection. (12 Dec 1998) |
| vaccination, infectious hepatitis | See Vaccination, hepatitis a. (12 Dec 1998) |
| vaccineation, serum hepatitis | See Vaccination, hepatitis b. (12 Dec 1998) |
| giant cell hepatitis | Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop. Synonym: giant cell hepatitis. (05 Mar 2000) |
| viral hepatitis | Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver. (12 Dec 1998) |
| viral hepatitis type A | A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom. Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|